Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Merrick I. Ross, Howard L. Kaufman, Keith A. Delman, Frances A. Collichio, Mohammed M. Milhem, Thomas Amatruda, Jonathan S. Zager, Lisa Chen, Igor Puzanov, Mark Shilkrut, Robert H.I. Andtbacka, Lee D. Cranmer, Eddy C. Hsueh
Publikováno v:
Annals of Surgical Oncology
Purpose Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we
Autor:
Neil Senzer, Igor Puzanov, Bin Yao, Gerald P. Linette, Lynn E. Spitler, Sanjiv S. Agarwala, Susan Doleman, Troy H. Guthrie, Jason Chesney, Ari M. Vanderwalde, Robert Coffin, Keith A. Delman, Lee D. Cranmer, Kevin J. Harrington, Karl D. Lewis, Gregory A. Daniels, Jennifer Gansert, Jonathan S. Zager, Merrick I. Ross, Brendan D. Curti, Ai Li, Mark R. Middleton, Howard L. Kaufman, Wilson H. Miller, Mohammed M. Milhem, Thomas Amatruda, Yining Ye, Frances A. Collichio, Robert H.I. Andtbacka
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(25)
Purpose Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1–derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic anti
Autor:
Jason Chesney, Kevin J. Harrington, Kate Liu, Mark Shilkrut, S. Fourie, Frances A. Collichio, Lydia Dreosti, N.M. Steven, Robert Coffin, John Nemunaitis, Robert H.I. Andtbacka, Ai Li, Thomas Amatruda, Merrick I. Ross, Howard L. Kaufman
Publikováno v:
Annals of Oncology. 25:iv382
Aim: T-VEC is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate in tumors and produce GM-CSF to enhance systemic antitumor immune responses. Compared to GM-CSF alone, T-VEC significantly improved durable response rate (DRR; p